Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
CAS Registry Number
1907685-81-7
Molecular formula
C10H15N2O7P
Molecular weight
306.21 g/mol
Drug class
Carbidopa prodrugpyridoxine-independent peripheral dopa-decarboxylase inhibitor component of VYALEV
Mechanism of action
Foscarbidopa is a phosphate prodrug converted to carbidopa, which inhibits peripheral aromatic L-amino-acid decarboxylase and reduces peripheral conversion of levodopa to dopamine, increasing levodopa availability to the brain. It is used as part of the fixed foscarbidopa/foslevodopa combination.
Indications / reported uses
Component of the fixed combination VYALEV (foscarbidopa/foslevodopa) for treatment of motor fluctuations in adults with advanced Parkinson disease; not a stand-alone approved indication
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Foscarbidopa PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Foscarbidopa Permitted Daily Exposure (PDE) report (the Foscarbidopa PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Foscarbidopa Occupational Exposure Limit (OEL) report (the Foscarbidopa OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.